Importance of Rapid and Effective Reduction of Blood Pressure in Treating Hypertension for the Prevention of Cardiovascular DiseasesA Lesson from the VALUE Study

被引:4
作者
Salvatore Di Somma
机构
[1] University ‘La Sapienza’,Department of Medicine, Emergency Medicine
[2] Sant’Andrea Hospital,undefined
关键词
Hypertensive Patient; Calcium Antagonist; Antihypertensive Drug; Amlodipine; Valsartan;
D O I
10.2165/00151642-200512030-00004
中图分类号
学科分类号
摘要
The efficacy of antihypertensive medications in reducing the high blood pressure (BP) levels in patients with hypertension has been demonstrated, but the incidence of cardiovascular diseases in treated hypertensive subjects is still higher compared with subjects with normal BP values. This discrepancy could chiefly stem from: (a) the inability of the pharmacological treatment to normalise BP levels in all treated patients; (b) poor pre-evaluation of cerebral, cardiac and renal damage involvement in treated patients; and (c) the inappropriate choice of antihypertensive drug. If we consider that the recent guidelines on the treatment of hypertension have further reduced the thresholds of normal BP values (e.g. 120–129mm Hg for systolic and 80–84mm Hg for diastolic BP), we can hypothesise that in Italy today optimal control of BP in patients with hypertension could be further reduced, when compared with the past, and could be estimated to be obtained at present in only 25% of treated patients. This situation is of course unacceptable and efforts should be made by educational institutions to recommend that physicians apply current recommendations from the guidelines, aiming at properly normalising BP in treated hypertensive patients.
引用
收藏
页码:135 / 140
页数:5
相关论文
共 24 条
[1]  
Dahlof B(2002)for The LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for End-point reduction in hypertension (LIFE) study: a randomised trial against atenolol Lancet 359 995-1003
[2]  
Devereux RB(2004)β-Blocker based antihypertensive therapy is associated with better control of blood pressure and short-term cardiovascular rish in hypertensive smokers (STEFI Study) High Blood Press Cardiovasc Prev 11 91-8
[3]  
Kjeldsen SE(2003)(ESC) guidelines for the management of arterial hypertension J Hypertens 21 1011-53
[4]  
Di Somma S(2001)Impact of high-normal BP on the risk of cardiovascular disease N Engl J Med 345 1291-7
[5]  
Micheli D(1996)Controlling hypertension: a research success story Arch Intern Med 156 1926-35
[6]  
Costa B(2002)Prospective Studies Collaboration. Age-specific relevance of usual BP to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies Lancet 360 1903-13
[7]  
Vasan RS(2004)Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) randomised trial Lancet 363 2022-31
[8]  
Larson MG(2004)BP dependent and independent effects of antihypertensive treatment on clinical events in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) Trial Lancet 363 2049-51
[9]  
Leip EP(1994)Hypertension as worsening factor for left ventricular contractility and function in patients with unstable angina High Blood Press Cardiovasc Prev 3 18-22
[10]  
Dustan HP(undefined)undefined undefined undefined undefined-undefined